Rewisca

Rewisca

pregabalin

Manufacturer:

KRKA

Distributor:

Uni Drug
Concise Prescribing Info
Contents
Pregabalin
Indications/Uses
Neuropathic pain which includes diabetic peripheral neuropathy & post-herpetic neuralgia in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Generalised anxiety disorder (GAD) in adults. Managemment of fibromyalgia.
Dosage/Direction for Use
Neuropathic pain Initially, 150 mg daily given as 2 or 3 divided doses. May be increased to 300 mg daily after 3-7 day interval. Max: 600 mg daily after an additional 7-day interval. Epilepsy Initially, 150 mg daily given as 2 or 3 divided doses. May be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. GAD Initially, 150 mg daily given as 2 or 3 divided doses. May be increased to 300 mg daily after 1 wk & 450 mg daily following an additional wk. Max: 600 mg daily after an additional wk. Fibromyalgia Initially, 75 mg bd. May be increased to 150 mg bd w/in 1 wk or if needed, further increased to 225 mg bd. Max: 450 mg daily. Renal impairment: CrCl ≥60 mL/min Initially, 150 mg daily bd or tds. Max: 600 mg daily bd or tds, ≥30-<60 mL/min Initially, 75 mg daily bd or tds. Max: 300 mg daily bd or tds, ≥15-<30 mL/min Initially, 25-50 mg once daily or bd. Max: 150 mg once daily or bd, <15 mL/min Initially, 25 mg once daily. Max: 75 mg once daily. Haemodialysis Supplementary dose: 25 mg (max: 100 mg).
Administration
May be taken with or without food.
Contraindications
Special Precautions
Discontinue immediately if symptoms of angioedema occur (eg, facial, perioral, or upper airway swelling). Diabetic patients who gain wt; may need to adjust hypoglycaemic medicinal products. Dizziness, somnolence; potential loss of consciousness, confusion & mental impairment; increase occurence of accidental injury (ie, fall) in older people.Transient visual blurring & other visual acuity changes. Evaluate patients for history of drug abuse & observe for signs of misuse or abuse. Patients w/ CHF. Discontinue if myopathy is diagnosed or suspected, or if markedly elevated creatine kinase levels occur. Risk of suicidal ideation & behavior. May influence the ability to drive & use machines. Renal impairment. Women of childbearing potential should use effective contraception. Pregnancy. Not recommended during lactation. Not recommended in childn <12 yr & adolescents 12-17 yr. Elderly >65 yr.
Adverse Reactions
Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, drunk & abnormal feeling, fatigue; increased wt.
Drug Interactions
May potentiate ethanol & lorazepam effects. Additive cognitive & gross motor function impairment w/ oxycodone. Potential resp failure & coma w/ other CNS depressants. Potential reduced lower GIT function w/ medications which may produce constipation eg, opioid analgesics.
MIMS Class
ATC Classification
N03AX16 - pregabalin ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Rewisca 75 mg hard cap
Packing/Price
30's
Form
Rewisca 150 mg hard cap
Packing/Price
30's
Form
Rewisca 25 mg hard capsule
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in